Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-09 04:42 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 4CompletedINTERVENTIONAL

A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)

ClinicalTrials.gov · NCT00734097 · Registry updated: 2012-10-10

Condition / research focus: Gastroesophageal Reflux Disease
Sponsor: AstraZeneca
Countries with listed sites: Argentina · Chile · Colombia · Venezuela
Registry dates and results: Start: 2007-11. Completion: 2008-10 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Esomeprazole 40 mg (drug) — also listed as: Nexium
Physical Exam (procedure)
Quality of Life Questionnaires (other)
pregnancy test, if applicable (procedure)

Where the study takes place — 10 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Research Site
Buenos Aires, Argentina
Site recruitment: Not reported
Research Site
Santiago, Chile
Site recruitment: Not reported
Research Site
Temuco, Chile
Site recruitment: Not reported
Research Site
Viña del Mar, Chile
Site recruitment: Not reported
Research Site
Barranquilla, Colombia
Site recruitment: Not reported
Research Site
Bogotá, Colombia
Site recruitment: Not reported
Research Site
Medellín, Colombia
Site recruitment: Not reported
Research Site
Barquisimeto, Venezuela
Site recruitment: Not reported
Research Site
Caracas, Venezuela
Site recruitment: Not reported
Research Site
San Cristóbal, Venezuela
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Intra-uterine Injection of Human Chorionic Gonadotrophin (hCG) Before Embryo Transfer

ClinicalTrials.gov · NCT01030393 · Registry updated: 2012-08-21

Condition / research focus: Infertility
Sponsor: The Egyptian IVF-ET Center
Countries with listed sites: Egypt
Registry dates and results: Start: 2010-01. Completion: 2011-02 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotrophin (drug) — also listed as: choriomon

Where the study takes place — 1 listed sites

The Egyptian IVF- ET center
Cairo, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Consumer in Stream and Container Collected Study

ClinicalTrials.gov · NCT01577901 · Registry updated: 2012-08-15

Condition / research focus: Determination of Pregnancy Status
Sponsor: SPD Development Company Limited
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2012-03. Completion: 2012-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Clearblue Advanced (other)

Where the study takes place — 1 listed sites

SPD Development Company Ltd.
Bedford, Bedfordshire, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Comparison of Single and Multiple-dose Methotrexate Therapy for Ectopic Pregnancy

ClinicalTrials.gov · NCT01662167 · Registry updated: 2012-08-10

Condition / research focus: Pregnancy, Ectopic
Sponsor: Hormozgan University of Medical Sciences
Countries with listed sites: Iran
Registry dates and results: Start: 2008-01. Completion: 2011-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Single (drug)
Multipe (drug)

Where the study takes place — 1 listed sites

Shariaty Hospital
Bandar Abbas, Hormozgan, Iran
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Schizophrenia Imaging

ClinicalTrials.gov · NCT01655472 · Registry updated: 2012-08-01

Condition / research focus: Foetal Differences Between Healthy and Schizophernic Parents
Sponsor: Tel-Aviv Sourasky Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2012-07. Completion: 2015-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

imaging follow up: MRI scan (device) — also listed as: 1. MRI 1.5 T & 3.0 T, MR systems, GE 1.5 & 3T Signa HDx MR system, General Electric Medical Technologies, 2. GE MEDICAL SYSTEMS, ULTRASOUND, GE Medical Systems Kretztechnik GmBH & Co OHG
imaging follow up: Ultrasonographic examination (device)

Where the study takes place — 8 listed sites

Abarbanel Mental Health Centre
Bat Yam, Israel
Site recruitment: Not reported
Beer Yaacov Mental health Centre
Beer Yaakov, Israel
Site recruitment: Not reported
Shalvata mental health centre
Hod HaSharon, Israel
Site recruitment: Not reported
Edith Wolfson Medical Centre
Holon, Israel
Site recruitment: Not reported
Geha mental health centre
Petah Tikva, Israel
Site recruitment: Not reported
Brill outpatient clinic
Tel Aviv, Israel
Site recruitment: Not reported
Sourasky Medical Centre
Tel Aviv, Israel
Site recruitment: Not reported
Chaim Sheba medical centre
Tel HaShomer, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableTerminatedINTERVENTIONAL

Polycystic Ovary Syndrome (PCOS) and In Vitro Fertilization (IVF): A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1

ClinicalTrials.gov · NCT00883766 · Registry updated: 2012-07-20

Condition / research focus: Polycystic Ovary Syndrome; In Vitro Fertilization
Sponsor: Fundacion Dexeus
Countries with listed sites: Spain
Registry dates and results: Start: 2009-04. Completion: 2012-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Controlled ovarian hyperstimulation for IVF with a long agonist protocol (other)
Controlled ovarian hyperstimulation for IVF with an antagonist protocol (other)

Where the study takes place — 1 listed sites

Institut Universitari Dexeus
Barcelona, Barcelona, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Ovarian Stimulation Using Recombinant Follicle-stimulating Hormone (FSH) and Gonadotrophin Releasing Hormone (GnRH) Agonist in Alternate Days

ClinicalTrials.gov · NCT01468441 · Registry updated: 2012-07-13

Condition / research focus: Infertility
Sponsor: Fertility - Assisted Fertilization Center
Countries with listed sites: Brazil
Registry dates and results: Start: 2011-09. Completion: 2012-03 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Triptorelin (drug) — also listed as: Gonapeptyl
Cetrorelix (drug) — also listed as: Cetrotide

Where the study takes place — 1 listed sites

Fertility - Assisted Fertilization Center
São Paulo, São Paulo, Brazil
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Technical Evaluation Of JewelPUMP In Type 1 Diabetic Patients Treated With Extern Insulin Pump

ClinicalTrials.gov · NCT01640210 · Registry updated: 2012-07-13

Condition / research focus: Type1diabetes
Sponsor: Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Countries with listed sites: France
Registry dates and results: Start: 2011-11. Completion: 2012-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

JewelPUMP (insulin patch pump) (device)

Where the study takes place — 2 listed sites

CHU Jean Minjoz
Besançon, France
Site recruitment: Not reported
University Hospital Grenoble
Grenoble, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP

ClinicalTrials.gov · NCT01623570 · Registry updated: 2012-06-20

Condition / research focus: Hypogonadotropic Hypogonadism
Sponsor: Centro Riproduzione e Andrologia
Countries with listed sites: Italy
Registry dates and results: Start: 2011-03. Completion: 2012-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pergoveris: 150IU r-hFSH + 75IU r-hLH (drug) — also listed as: Pergoveris
Menopur: HMG-HP (150 IU) (drug) — also listed as: Menopur

Where the study takes place — 1 listed sites

Centro Riproduzione e Andrologia
Taranto, Italy, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers

ClinicalTrials.gov · NCT01009723 · Registry updated: 2012-06-08

Condition / research focus: Preterm Delivery
Sponsor: Esoterix Genetic Laboratories, LLC
Countries with listed sites: United States
Registry dates and results: Start: 2010-03. Completion: 2012-07 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 2 listed sites

Integrated Genetics
Westborough, Massachusetts, United States
Site recruitment: Not reported
Integrated Genetics
Santa Fe, New Mexico, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Study on Influence of Leutinizing Hormone (LH) on Oocyte Maturity

ClinicalTrials.gov · NCT01595334 · Registry updated: 2012-05-25

Condition / research focus: Infertility
Sponsor: Southern Cross Fertility Centre
Countries with listed sites: India
Registry dates and results: Start: 2012-04. Completion: 2012-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cetrorelix (drug) — also listed as: Cetrotide
Luprolide Acetate (drug) — also listed as: Lupron

Where the study takes place — 3 listed sites

Sat Kaival Hospital Pvt. Ltd.
Anand, Gujarat, India
Site recruitment: Recruiting
Disha Fertility & Surgical Hospital
Indore, Madhya Pradesh, India
Site recruitment: Recruiting
Southern Cross Fertility Center
Mumbai, Maharashtra, India
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effects of Medications in Patients With Hypogonadism

ClinicalTrials.gov · NCT01601327 · Registry updated: 2012-05-18

Condition / research focus: Idiopathic Hypogonadotropic Hypogonadism
Sponsor: Gulhane School of Medicine
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2008-01. Completion: 2012-03 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Testosterone enanthate (Sustanon 250 mg) (drug)
Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU) (drug)
Testosteron gel (Testojel 50 mg) (drug)

Where the study takes place — 2 listed sites

Gulhane School of Medicine Dep. of Endocrine and Metabolism
Ankara, Turkey (Türkiye)
Site recruitment: Not reported
Gulhane School of Medicine Dep. of Endocrinology and Metabolism
Ankara, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Does Follow-up With Serum Beta Human Chorionic Gonadotropin (BhCG) Simplify Medical Abortion?

ClinicalTrials.gov · NCT00907725 · Registry updated: 2012-05-10

Condition / research focus: Medical Abortion
Sponsor: Planned Parenthood League of Massachusetts
Countries with listed sites: United States
Registry dates and results: Start: 2009-05. Completion: 2010-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

serum BhCG follow-up (other)
ultrasonographic follow-up (other)

Where the study takes place — 1 listed sites

Planned Parenthood League of Massachusetts
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer

ClinicalTrials.gov · NCT00884221 · Registry updated: 2012-04-20

Condition / research focus: Infertility
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: Belgium · Czechia · Denmark · Poland · Spain · Sweden · Turkey (Türkiye)
Registry dates and results: Start: 2009-07. Completion: 2011-01 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Highly purified menotrophin (drug) — also listed as: HP-hMG, MENOPUR
Recombinant FSH (drug) — also listed as: Follitrophin-beta, PUREGON, FOLLISTIM

Where the study takes place — 25 listed sites

ERASME Hospital
Anderlecht, Belgium
Site recruitment: Not reported
UZ Brussel
Brussels, Belgium
Site recruitment: Not reported
UZ Antwerpen
Edegem, Belgium
Site recruitment: Not reported
UZ Gent
Ghent, Belgium
Site recruitment: Not reported
IVF Institute
Pilsen, Czechia
Site recruitment: Not reported
ISCARE IVF a.s.
Prague, Czechia
Site recruitment: Not reported
Pronatal
Prague, Czechia
Site recruitment: Not reported
H:S Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
Amtssygehuset Herlev
Herlev, Denmark
Site recruitment: Not reported
Sygehus Vestsjælland
Holbæk, Denmark
Site recruitment: Not reported
H:S Hvidovre Hospital
Hvidovre, Denmark
Site recruitment: Not reported
KRIOBANK
Bialystok, Poland
Site recruitment: Not reported
nOvum
Warsaw, Poland
Site recruitment: Not reported
IU Dexeus
Barcelona, Spain
Site recruitment: Not reported
GINEFIV, Madrid
Madrid, Spain
Site recruitment: Not reported
IVI Madrid
Madrid, Spain
Site recruitment: Not reported
Ginemed
Seville, Spain
Site recruitment: Not reported
IVI Sevilla
Seville, Spain
Site recruitment: Not reported
IVI Valencia
Valencia, Spain
Site recruitment: Not reported
Fertilitetscentrum AB Gothenburg
Gothenburg, Sweden
Site recruitment: Not reported
IVF-kliniken CURA
Malmö, Sweden
Site recruitment: Not reported
RMC, Malmö
Malmö, Sweden
Site recruitment: Not reported
Hacettepe University
Ankara, Turkey (Türkiye)
Site recruitment: Not reported
American Hospital
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported
Memorial Hospital
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)

ClinicalTrials.gov · NCT01004770 · Registry updated: 2012-04-05

Condition / research focus: Healthy
Sponsor: GE Healthcare
Countries with listed sites: United States
Registry dates and results: Start: 2009-10. Completion: 2010-05 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GE-145 (AN113111) Injection (drug) — also listed as: AH113111, GE-145
Visipaque (iodixanol) Injection (drug) — also listed as: Visipaque, Iodixanol

Where the study takes place — 1 listed sites

GE Healthcare
Princeton, New Jersey, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Ovarian Hyperstimulation Syndrome and Cabergoline

ClinicalTrials.gov · NCT01569256 · Registry updated: 2012-04-04

Condition / research focus: Polycystic Ovarian Syndrome; Ovarian Hyperstimulation Syndrome
Sponsor: Etlik Zubeyde Hanim Womens' Health and Teaching Hospital
Countries with listed sites: No country reported
Registry dates and results: Start: 2008-03. Completion: 2009-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cabergoline (drug) — also listed as: Dostinex

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableTerminatedINTERVENTIONAL

In Vitro Fertilization Outcomes of Two Treatment Protocols in Women With Polycystic Ovary Syndrome

ClinicalTrials.gov · NCT01354275 · Registry updated: 2012-02-03

Condition / research focus: PCOS GnRH Antagonist and GnRH Agonist IVF/ICSI Cycles
Sponsor: Bulent Haydardedeoglu
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2009-03. Completion: 2011-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

To compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle (other)
GnRH Antagonist (other)

Where the study takes place — 1 listed sites

Bulent Haydardedeoglu
Adana, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)

ClinicalTrials.gov · NCT00805935 · Registry updated: 2012-01-27

Condition / research focus: Polycystic Ovarian Syndrome; Infertility
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: United States
Registry dates and results: Start: 2009-01. Completion: 2010-09 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Menotropin (drug) — also listed as: Menopur®
Progesterone vaginal insert (drug) — also listed as: Endometrin®
Follitropin beta (drug) — also listed as: Follistim Pen®
Progesterone in oil (drug)
leuprolide acetate (drug) — also listed as: Lupron

Where the study takes place — 6 listed sites

Conceptions Reproductive Associates of Colorado
Littleton, Colorado, United States
Site recruitment: Not reported
Women's Medical Research Group LLC, Florida
Clearwater, Florida, United States
Site recruitment: Not reported
Fertility Center of Illinois
Chicago, Illinois, United States
Site recruitment: Not reported
Weill Cornell Medical College
New York, New York, United States
Site recruitment: Not reported
Women & Infants' Hospital of RI
Providence, Rhode Island, United States
Site recruitment: Not reported
Center for Assisted Reproduction
Bedford, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Efficacy of Low Dose hCG on Oocyte Maturity in Poor Responder Women Undergoing Intracytoplasmic Sperm Injection

ClinicalTrials.gov · NCT01509833 · Registry updated: 2012-01-13

Condition / research focus: Infertility
Sponsor: Royan Institute
Countries with listed sites: Iran
Registry dates and results: Start: 2009-10. Completion: 2011-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

rFSH (drug)
hCG (drug)
hCG (drug)

Where the study takes place — 1 listed sites

Royan Institute
Tehran, Iran
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Metformin in Assisted Reproduction-MET-AR-study

ClinicalTrials.gov · NCT00159575 · Registry updated: 2012-01-05

Condition / research focus: Polycystic Ovary Syndrome
Sponsor: Norwegian University of Science and Technology
Countries with listed sites: Norway
Registry dates and results: Start: 2005-03. Completion: 2010-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Metformin / Placebo treatment for 4 months (drug)

Where the study takes place — 2 listed sites

Sigrun Kjøtrød
Trondheim, Norway
Site recruitment: Not reported
Fertility UNit- -St Olavs Hospital
Trondheim, Norway
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-09 04:42 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 4CompletedINTERVENTIONAL

A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)

ClinicalTrials.gov · NCT00734097 · Registry updated: 2012-10-10

Condition / research focus: Gastroesophageal Reflux Disease
Sponsor: AstraZeneca
Countries with listed sites: Argentina · Chile · Colombia · Venezuela
Registry dates and results: Start: 2007-11. Completion: 2008-10 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Esomeprazole 40 mg (drug) — also listed as: Nexium
Physical Exam (procedure)
Quality of Life Questionnaires (other)
pregnancy test, if applicable (procedure)

Where the study takes place — 10 listed sites

Research Site
Buenos Aires, Argentina
Site recruitment: Not reported
Research Site
Santiago, Chile
Site recruitment: Not reported
Research Site
Temuco, Chile
Site recruitment: Not reported
Research Site
Viña del Mar, Chile
Site recruitment: Not reported
Research Site
Barranquilla, Colombia
Site recruitment: Not reported
Research Site
Bogotá, Colombia
Site recruitment: Not reported
Research Site
Medellín, Colombia
Site recruitment: Not reported
Research Site
Barquisimeto, Venezuela
Site recruitment: Not reported
Research Site
Caracas, Venezuela
Site recruitment: Not reported
Research Site
San Cristóbal, Venezuela
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Intra-uterine Injection of Human Chorionic Gonadotrophin (hCG) Before Embryo Transfer

ClinicalTrials.gov · NCT01030393 · Registry updated: 2012-08-21

Condition / research focus: Infertility
Sponsor: The Egyptian IVF-ET Center
Countries with listed sites: Egypt
Registry dates and results: Start: 2010-01. Completion: 2011-02 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotrophin (drug) — also listed as: choriomon

Where the study takes place — 1 listed sites

The Egyptian IVF- ET center
Cairo, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Consumer in Stream and Container Collected Study

ClinicalTrials.gov · NCT01577901 · Registry updated: 2012-08-15

Condition / research focus: Determination of Pregnancy Status
Sponsor: SPD Development Company Limited
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2012-03. Completion: 2012-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Clearblue Advanced (other)

Where the study takes place — 1 listed sites

SPD Development Company Ltd.
Bedford, Bedfordshire, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Comparison of Single and Multiple-dose Methotrexate Therapy for Ectopic Pregnancy

ClinicalTrials.gov · NCT01662167 · Registry updated: 2012-08-10

Condition / research focus: Pregnancy, Ectopic
Sponsor: Hormozgan University of Medical Sciences
Countries with listed sites: Iran
Registry dates and results: Start: 2008-01. Completion: 2011-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Single (drug)
Multipe (drug)

Where the study takes place — 1 listed sites

Shariaty Hospital
Bandar Abbas, Hormozgan, Iran
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Schizophrenia Imaging

ClinicalTrials.gov · NCT01655472 · Registry updated: 2012-08-01

Condition / research focus: Foetal Differences Between Healthy and Schizophernic Parents
Sponsor: Tel-Aviv Sourasky Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2012-07. Completion: 2015-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

imaging follow up: MRI scan (device) — also listed as: 1. MRI 1.5 T & 3.0 T, MR systems, GE 1.5 & 3T Signa HDx MR system, General Electric Medical Technologies, 2. GE MEDICAL SYSTEMS, ULTRASOUND, GE Medical Systems Kretztechnik GmBH & Co OHG
imaging follow up: Ultrasonographic examination (device)

Where the study takes place — 8 listed sites

Abarbanel Mental Health Centre
Bat Yam, Israel
Site recruitment: Not reported
Beer Yaacov Mental health Centre
Beer Yaakov, Israel
Site recruitment: Not reported
Shalvata mental health centre
Hod HaSharon, Israel
Site recruitment: Not reported
Edith Wolfson Medical Centre
Holon, Israel
Site recruitment: Not reported
Geha mental health centre
Petah Tikva, Israel
Site recruitment: Not reported
Brill outpatient clinic
Tel Aviv, Israel
Site recruitment: Not reported
Sourasky Medical Centre
Tel Aviv, Israel
Site recruitment: Not reported
Chaim Sheba medical centre
Tel HaShomer, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableTerminatedINTERVENTIONAL

Polycystic Ovary Syndrome (PCOS) and In Vitro Fertilization (IVF): A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1

ClinicalTrials.gov · NCT00883766 · Registry updated: 2012-07-20

Condition / research focus: Polycystic Ovary Syndrome; In Vitro Fertilization
Sponsor: Fundacion Dexeus
Countries with listed sites: Spain
Registry dates and results: Start: 2009-04. Completion: 2012-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Controlled ovarian hyperstimulation for IVF with a long agonist protocol (other)
Controlled ovarian hyperstimulation for IVF with an antagonist protocol (other)

Where the study takes place — 1 listed sites

Institut Universitari Dexeus
Barcelona, Barcelona, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Ovarian Stimulation Using Recombinant Follicle-stimulating Hormone (FSH) and Gonadotrophin Releasing Hormone (GnRH) Agonist in Alternate Days

ClinicalTrials.gov · NCT01468441 · Registry updated: 2012-07-13

Condition / research focus: Infertility
Sponsor: Fertility - Assisted Fertilization Center
Countries with listed sites: Brazil
Registry dates and results: Start: 2011-09. Completion: 2012-03 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Triptorelin (drug) — also listed as: Gonapeptyl
Cetrorelix (drug) — also listed as: Cetrotide

Where the study takes place — 1 listed sites

Fertility - Assisted Fertilization Center
São Paulo, São Paulo, Brazil
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Technical Evaluation Of JewelPUMP In Type 1 Diabetic Patients Treated With Extern Insulin Pump

ClinicalTrials.gov · NCT01640210 · Registry updated: 2012-07-13

Condition / research focus: Type1diabetes
Sponsor: Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Countries with listed sites: France
Registry dates and results: Start: 2011-11. Completion: 2012-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

JewelPUMP (insulin patch pump) (device)

Where the study takes place — 2 listed sites

CHU Jean Minjoz
Besançon, France
Site recruitment: Not reported
University Hospital Grenoble
Grenoble, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP

ClinicalTrials.gov · NCT01623570 · Registry updated: 2012-06-20

Condition / research focus: Hypogonadotropic Hypogonadism
Sponsor: Centro Riproduzione e Andrologia
Countries with listed sites: Italy
Registry dates and results: Start: 2011-03. Completion: 2012-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pergoveris: 150IU r-hFSH + 75IU r-hLH (drug) — also listed as: Pergoveris
Menopur: HMG-HP (150 IU) (drug) — also listed as: Menopur

Where the study takes place — 1 listed sites

Centro Riproduzione e Andrologia
Taranto, Italy, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers

ClinicalTrials.gov · NCT01009723 · Registry updated: 2012-06-08

Condition / research focus: Preterm Delivery
Sponsor: Esoterix Genetic Laboratories, LLC
Countries with listed sites: United States
Registry dates and results: Start: 2010-03. Completion: 2012-07 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 2 listed sites

Integrated Genetics
Westborough, Massachusetts, United States
Site recruitment: Not reported
Integrated Genetics
Santa Fe, New Mexico, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Study on Influence of Leutinizing Hormone (LH) on Oocyte Maturity

ClinicalTrials.gov · NCT01595334 · Registry updated: 2012-05-25

Condition / research focus: Infertility
Sponsor: Southern Cross Fertility Centre
Countries with listed sites: India
Registry dates and results: Start: 2012-04. Completion: 2012-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cetrorelix (drug) — also listed as: Cetrotide
Luprolide Acetate (drug) — also listed as: Lupron

Where the study takes place — 3 listed sites

Sat Kaival Hospital Pvt. Ltd.
Anand, Gujarat, India
Site recruitment: Recruiting
Disha Fertility & Surgical Hospital
Indore, Madhya Pradesh, India
Site recruitment: Recruiting
Southern Cross Fertility Center
Mumbai, Maharashtra, India
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effects of Medications in Patients With Hypogonadism

ClinicalTrials.gov · NCT01601327 · Registry updated: 2012-05-18

Condition / research focus: Idiopathic Hypogonadotropic Hypogonadism
Sponsor: Gulhane School of Medicine
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2008-01. Completion: 2012-03 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Testosterone enanthate (Sustanon 250 mg) (drug)
Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU) (drug)
Testosteron gel (Testojel 50 mg) (drug)

Where the study takes place — 2 listed sites

Gulhane School of Medicine Dep. of Endocrine and Metabolism
Ankara, Turkey (Türkiye)
Site recruitment: Not reported
Gulhane School of Medicine Dep. of Endocrinology and Metabolism
Ankara, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Does Follow-up With Serum Beta Human Chorionic Gonadotropin (BhCG) Simplify Medical Abortion?

ClinicalTrials.gov · NCT00907725 · Registry updated: 2012-05-10

Condition / research focus: Medical Abortion
Sponsor: Planned Parenthood League of Massachusetts
Countries with listed sites: United States
Registry dates and results: Start: 2009-05. Completion: 2010-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

serum BhCG follow-up (other)
ultrasonographic follow-up (other)

Where the study takes place — 1 listed sites

Planned Parenthood League of Massachusetts
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer

ClinicalTrials.gov · NCT00884221 · Registry updated: 2012-04-20

Condition / research focus: Infertility
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: Belgium · Czechia · Denmark · Poland · Spain · Sweden · Turkey (Türkiye)
Registry dates and results: Start: 2009-07. Completion: 2011-01 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Highly purified menotrophin (drug) — also listed as: HP-hMG, MENOPUR
Recombinant FSH (drug) — also listed as: Follitrophin-beta, PUREGON, FOLLISTIM

Where the study takes place — 25 listed sites

ERASME Hospital
Anderlecht, Belgium
Site recruitment: Not reported
UZ Brussel
Brussels, Belgium
Site recruitment: Not reported
UZ Antwerpen
Edegem, Belgium
Site recruitment: Not reported
UZ Gent
Ghent, Belgium
Site recruitment: Not reported
IVF Institute
Pilsen, Czechia
Site recruitment: Not reported
ISCARE IVF a.s.
Prague, Czechia
Site recruitment: Not reported
Pronatal
Prague, Czechia
Site recruitment: Not reported
H:S Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
Amtssygehuset Herlev
Herlev, Denmark
Site recruitment: Not reported
Sygehus Vestsjælland
Holbæk, Denmark
Site recruitment: Not reported
H:S Hvidovre Hospital
Hvidovre, Denmark
Site recruitment: Not reported
KRIOBANK
Bialystok, Poland
Site recruitment: Not reported
nOvum
Warsaw, Poland
Site recruitment: Not reported
IU Dexeus
Barcelona, Spain
Site recruitment: Not reported
GINEFIV, Madrid
Madrid, Spain
Site recruitment: Not reported
IVI Madrid
Madrid, Spain
Site recruitment: Not reported
Ginemed
Seville, Spain
Site recruitment: Not reported
IVI Sevilla
Seville, Spain
Site recruitment: Not reported
IVI Valencia
Valencia, Spain
Site recruitment: Not reported
Fertilitetscentrum AB Gothenburg
Gothenburg, Sweden
Site recruitment: Not reported
IVF-kliniken CURA
Malmö, Sweden
Site recruitment: Not reported
RMC, Malmö
Malmö, Sweden
Site recruitment: Not reported
Hacettepe University
Ankara, Turkey (Türkiye)
Site recruitment: Not reported
American Hospital
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported
Memorial Hospital
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)

ClinicalTrials.gov · NCT01004770 · Registry updated: 2012-04-05

Condition / research focus: Healthy
Sponsor: GE Healthcare
Countries with listed sites: United States
Registry dates and results: Start: 2009-10. Completion: 2010-05 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GE-145 (AN113111) Injection (drug) — also listed as: AH113111, GE-145
Visipaque (iodixanol) Injection (drug) — also listed as: Visipaque, Iodixanol

Where the study takes place — 1 listed sites

GE Healthcare
Princeton, New Jersey, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Ovarian Hyperstimulation Syndrome and Cabergoline

ClinicalTrials.gov · NCT01569256 · Registry updated: 2012-04-04

Condition / research focus: Polycystic Ovarian Syndrome; Ovarian Hyperstimulation Syndrome
Sponsor: Etlik Zubeyde Hanim Womens' Health and Teaching Hospital
Countries with listed sites: No country reported
Registry dates and results: Start: 2008-03. Completion: 2009-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cabergoline (drug) — also listed as: Dostinex

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableTerminatedINTERVENTIONAL

In Vitro Fertilization Outcomes of Two Treatment Protocols in Women With Polycystic Ovary Syndrome

ClinicalTrials.gov · NCT01354275 · Registry updated: 2012-02-03

Condition / research focus: PCOS GnRH Antagonist and GnRH Agonist IVF/ICSI Cycles
Sponsor: Bulent Haydardedeoglu
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2009-03. Completion: 2011-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

To compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle (other)
GnRH Antagonist (other)

Where the study takes place — 1 listed sites

Bulent Haydardedeoglu
Adana, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)

ClinicalTrials.gov · NCT00805935 · Registry updated: 2012-01-27

Condition / research focus: Polycystic Ovarian Syndrome; Infertility
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: United States
Registry dates and results: Start: 2009-01. Completion: 2010-09 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Menotropin (drug) — also listed as: Menopur®
Progesterone vaginal insert (drug) — also listed as: Endometrin®
Follitropin beta (drug) — also listed as: Follistim Pen®
Progesterone in oil (drug)
leuprolide acetate (drug) — also listed as: Lupron

Where the study takes place — 6 listed sites

Conceptions Reproductive Associates of Colorado
Littleton, Colorado, United States
Site recruitment: Not reported
Women's Medical Research Group LLC, Florida
Clearwater, Florida, United States
Site recruitment: Not reported
Fertility Center of Illinois
Chicago, Illinois, United States
Site recruitment: Not reported
Weill Cornell Medical College
New York, New York, United States
Site recruitment: Not reported
Women & Infants' Hospital of RI
Providence, Rhode Island, United States
Site recruitment: Not reported
Center for Assisted Reproduction
Bedford, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Efficacy of Low Dose hCG on Oocyte Maturity in Poor Responder Women Undergoing Intracytoplasmic Sperm Injection

ClinicalTrials.gov · NCT01509833 · Registry updated: 2012-01-13

Condition / research focus: Infertility
Sponsor: Royan Institute
Countries with listed sites: Iran
Registry dates and results: Start: 2009-10. Completion: 2011-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

rFSH (drug)
hCG (drug)
hCG (drug)

Where the study takes place — 1 listed sites

Royan Institute
Tehran, Iran
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Metformin in Assisted Reproduction-MET-AR-study

ClinicalTrials.gov · NCT00159575 · Registry updated: 2012-01-05

Condition / research focus: Polycystic Ovary Syndrome
Sponsor: Norwegian University of Science and Technology
Countries with listed sites: Norway
Registry dates and results: Start: 2005-03. Completion: 2010-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Metformin / Placebo treatment for 4 months (drug)

Where the study takes place — 2 listed sites

Sigrun Kjøtrød
Trondheim, Norway
Site recruitment: Not reported
Fertility UNit- -St Olavs Hospital
Trondheim, Norway
Site recruitment: Not reported

Original record, eligibility, contacts and results →